David is a physician-scientist with extensive biopharma R&D experience across a range of therapeutic areas and modalities – particularly focusing on diabetes and obesity. While at Merck and Eli Lilly, David’s efforts included oversight of teams that discovered and developed: sitagliptin (Januvia), dulaglutide (Trulicity), tirzepatide (Mounjaro, Zepbound), and Lyumjevplus other pipeline additions for musculoskeletal and cardiorenal disorders. Other roles included business development and venture investing (Lilly) as well as several biotech positions – he is currently CSO at Variant Bio – a human genetics-driven drug discovery company.
David has a B.S. from Brown U. and M.D. from U. of Cincinnati. He received clinical and research training at Harvard Medical School and then served on the faculty for several years. David has published more than 140 peer-reviewed papers; his honors include election to the American Society of Clinical Investigation, the Association of American Physicians, and appointment as an adjunct professor at the Karolinska Institute.
